Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective

Current Opinion in Chemical Biology

Volumn 14, Issue 3, 2010, Pages 308-314

  Bauer, Renato A ^a   Wurst, Jacqueline M ^a   Tan, Derek S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABYSSOMICIN C; ANTINEOPLASTIC AGENT; AVRAINVILLAMIDE; E 7107; FR 901464; GEMMACIN; LACTAM CARBOXAMIDE; NUCLEIC ACID; PLADIENOLIDE B; RABOTNIKININ; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CLINICAL TRIAL; DNA REPAIR; DNA SYNTHESIS; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MOLECULAR LIBRARY; MOLECULAR PROBE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN INTERACTION MAPPING; SMALL MOLECULE LIBRARIES;

EID: 77952545822     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2010.02.001     Document Type: Review

References (50)

1. Lazo J.S., Brady L.S., and Dingledine R. Building a pharmacological lexicon: small molecule discovery in academia. Mol Pharmacol 72 (2007) 1-7. An excellent overview of academic screening in the context of the NIH Molecular Libraries Screening Center Network (MLSCN).
2. Overington J.P., Al-Lazikani B., and Hopkins A.L. How many drug targets are there?. Nat Rev Drug Discov 5 (2006) 993-996. A comprehensive effort to identify and classify the biological targets of all existing drugs. One key finding is that small molecule drugs modulate only 207 targets encoded in the human genome.
3. Hopkins A.L., and Groom C.R. The druggable genome. Nat Rev Drug Discov 1 (2002) 727-730
4. Dobson C.M. Chemical space and biology. Nature 432 (2004) 824-828. An excellent introduction to the concept of chemical space and its interactions with biology.
5. Bohacek R.S., McMartin C., and Guida W.C. The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 16 (1996) 3-50
6. Hert J., Irwin J.J., Laggner C., Keiser M.J., and Shoichet B.K. Quantifying biogenic bias in screening libraries. Nat Chem Biol 5 (2009) 479-483. A seminal analysis of the structural similarity between existing libraries and naturally occurring molecules, leading to the proposal that new libraries should be developed based on other naturally occurring scaffolds that are also biologically validated but remain underrepresented in screening collections.
7. Fink T., and Reymond J.-L. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: Assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J Chem Inf Model 47 (2007) 342-353
8. Newman D.J., Cragg G.M., and Snader K.M. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66 (2003) 1022-1037
9. Driggers E.M., Hale S.P., Lee J., and Terrett N.K. The exploration of macrocycles for drug discovery - an underexploited structural class. Nat Rev Drug Discov 7 (2008) 608-624. An excellent discussion of the functional capabilities of macrocycles and their underutilization in drug discovery.
10. Feher M., and Schmidt J.M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43 (2003) 218-227. An important large-scale analysis of structural differences between approved drugs, natural products and commercial combinatorial libraries.
11. Shelat A.A., and Guy R.K. The interdependence between screening methods and screening libraries. Curr Opin Chem Biol 11 (2007) 244-251. A recent analysis of drugs, natural products and diversity libraries using principal component analysis and radar plots of molecular descriptors.
12. Tan D.S. Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol 1 (2005) 74-84
13. Top 200 Brand-Name Drugs by Retail Dollars in 2006 on World Wide Web URL: http://drugtopics.modernmedicine.com/.
14. Ganesan. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol 12 (2008) 306-317. Identification of 24 natural products that have led directly to approved drugs since 1970 and discussion of their structural properties.
15. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23 (1997) 3-25
16. Dobson P.D., and Kell D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat Rev Drug Discov 7 (2008) 205-220
17. Wells J.A., and McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450 (2007) 1001-1009. An excellent review of recent successes in developing small molecules that disrupt protein-protein interactions.
18. Whitty A., and Kumaravel G. Between a rock and a hard place?. Nat Chem Biol 2 (2006) 112-118
19. Spencer R.W. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol Bioeng 61 (1998) 61-67
20. Cochran A.G. Antagonists of protein-protein interactions. Chem Biol 7 (2000) R85-R94
21. Chonghaile T.N., and Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 27 (2009) S149-S157
22. Kang M.H., and Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15 (2009) 1126-1132
23. Wahl M.C., Will C.L., and Luehrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 136 (2009) 701-718
24. Rymond B. Targeting the spliceosome. Nat Chem Biol 3 (2007) 533-535
25. Kaida D., Motoyoshi H., Tashiro E., Nojima T., Hagiwara M., Ishigami K., Watanabe H., Kitahara T., Yoshida T., Nakajima H., et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 3 (2007) 576-583
26. Kotake Y., Sagane K., Owa T., Mimori-Kiyosue Y., Shimizu H., Uesugi M., Ishihama Y., Iwata M., and Mizui Y. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 3 (2007) 570-575
27. Golas M.M., Sander B., Will C.L., Luehrmann R., and Stark H. Molecular architecture of the multiprotein splicing factor SF3b. Science 300 (2003) 980-984
28. Rubin L.L., and de Sauvage F.J. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 5 (2006) 1026-1033
29. Stanton B.Z., Peng L.F., Maloof N., Nakai K., Wang X., Duffner J.L., Taveras K.M., Hyman J.M., Lee S.W., Koehler A.N., et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol 5 (2009) 154-156
30. Peng L.F., Stanton B.Z., Maloof N., Wang X., and Schreiber S.L. Syntheses of aminoalcohol-derived macrocycles leading to a small-molecule binder to and inhibitor of Sonic Hedgehog. Bioorg Med Chem Lett 19 (2009) 6319-6325
31. Berg T. Inhibition of transcription factors with small organic molecules. Curr Opin Chem Biol 12 (2008) 464-471. A review focused on recent successes in developing small molecules that inhibit dimeric transcription factors.
32. Arndt H.-D. Small molecule modulators of transcription. Angew Chem Int Ed 45 (2006) 4552-4560. An excellent review of small molecules that inhibit transcription factors and interactions with coregulatory proteins.
33. Pommier Y., and Marchand C. Interfacial inhibitors of protein-nucleic acid interactions. Curr Med Chem: Anti-Cancer Agents 5 (2005) 421-429
34. Moore P.B., and Steitz T.A. The structural basis of large ribosomal subunit function. Annu Rev Biochem 72 (2003) 813-850
35. Grisendi S., Mecucci C., Falini B., and Pandolfi P.P. Nucleophosmin and cancer. Nat Rev Cancer 6 (2006) 493-505
36. Wulff J.E., Siegrist R., and Myers A.G. The natural product avrainvillamide binds to the oncoprotein nucleophosmin. J Am Chem Soc 129 (2007) 14444-14451
37. Fenical W, Jensen PR, Cheng XC: Avrainvillamide, a cytotoxic marine natural product, and the derivatives thereof. US Patent 2000, 6066635.
38. Grummitt C.G., Townsley F.M., Johnson C.M., Warren A.J., and Bycroft M. Structural consequences of nucleophosmin mutations in acute myeloid leukemia. J Biol Chem 283 (2008) 23326-23332
39. Grier D.G., Thompson A., Kwasniewska A., McGonigle G.J., Halliday H.L., and Lappin T.R. The pathophysiology of HOX genes and their role in cancer. J Pathol 205 (2005) 154-171
40. Ng P.Y., Tang Y., Knosp W.M., Stadler H.S., and Shaw J.T. Synthesis of diverse lactam carboxamides leading to the discovery of a new transcription-factor inhibitor. Angew Chem Int Ed 46 (2007) 5352-5355
41. Nay B., Riache N., and Evanno L. Chemistry and biology of non-tetramic γ-hydroxy-γ-lactams and γ-alkylidene-γ-lactams from natural sources. Nat Prod Rep 26 (2009) 1044-1062
42. Fischbach M.A., and Walsh C.T. Antibiotics for emerging pathogens. Science 325 (2009) 1089-1093
43. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6 (2007) 29-40. An important report on GlaxoSmithKline's antibacterial screening campaigns and reasons for the disappointing results, including the need for increased chemical diversity in screening collections.
44. O'Shea R., and Moser H.E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 51 (2008) 2871-2878. A key illustration of the structural and physicochemical differences between antibacterials and other classes of drugs.
45. Bister B., Bischoff D., Stroebele M., Riedlinger J., Reicke A., Wolter F., Bull A.T., Zaehner H., Fiedler H.-P., and Süssmuth R.D. Abyssomicin C - a polycyclic antibiotic from a marine Verrucosispora strain as an inhibitor of the p-aminobenzoic acid/tetrahydrofolate biosynthesis pathway. Angew Chem Int Ed 43 (2004) 2574-2576
46. Nicolaou K.C., and Harrison S.T. Total synthesis of abyssomicin C and atrop-abyssomicin C. Angew Chem Int Ed 45 (2006) 3256-3260
47. Keller S., Schadt H.S., Ortel I., and Süssmuth R.D. Action of atrop-abyssomicin C as an inhibitor of 4-amino-4-deoxychorismate synthase PabB. Angew Chem Int Ed 46 (2007) 8284-8286
48. Walsh C. Antibiotics: Actions, Origins, Resistance (2003), ASM Press
49. Thomas G.L., Spandl R.J., Glansdorp F.G., Welch M., Bender A., Cockfield J., Lindsay J.A., Bryant C., Brown D.F.J., Loiseleur O., et al. Anti-MRSA agent discovery using diversity-oriented synthesis. Angew Chem Int Ed 47 (2008) 2808-2812
50. Shelat A.A., and Guy R.K. Scaffold composition and biological relevance of screening libraries. Nat Chem Biol 3 (2007) 442-446. A network graph approach for assessing and visualizing scaffold similarity.